Loading
A phase 3 trial of PM8002, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) is a phase 3 interventional study registered as NCT07361510 by Bristol-Myers Squibb, with 750 participants planned, started 2026-03-12 and due to reach its primary completion in 2031-10-14. Interventions recorded: Pumitamig, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.